Relationship between cytokine gene single nucleotide polymorphisms and symptom burden and quality of life in lung cancer survivors

Cancer

Volumn 116, Issue 17, 2010, Pages 4103-4113

  Rausch, Sarah M ^a   Clark, Matthew M ^b   Patten, Christi ^b   Liu, Heshan ^b   Felten, Sara ^b   Li, Yafei ^b   Sloan, Jeff ^b   Yang, Ping ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Cytokine; Lung cancer; Quality of life; Single nucleotide polymorphisms

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ADULT; AGED; APPETITE; ARTICLE; CANCER STAGING; CANCER SURVIVOR; CANCER SUSCEPTIBILITY; CAUCASIAN; COUGHING; DYSPNEA; EMOTION; FATIGUE; FEMALE; GENOTYPE; HEMOPTYSIS; HUMAN; INTERNAL CONSISTENCY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SENSITIVITY AND SPECIFICITY; SHORT FORM 8; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL STATUS; SYMPTOMATOLOGY; GENETICS; HEALTH STATUS; IMMUNOLOGY; LUNG TUMOR; MIDDLE AGED; PSYCHOLOGY; SURVIVOR; TREATMENT OUTCOME;

ADULT; AGED; APPETITE; CYTOKINES; FATIGUE; FEMALE; HEALTH STATUS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PAIN; POLYMORPHISM, SINGLE NUCLEOTIDE; QUALITY OF LIFE; SURVIVORS; TREATMENT OUTCOME;

EID: 77956814559     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25255     Document Type: Article

References (81)

1. American Cancer Society (ACS). Cancer Facts and Figures 2008. Atlanta, GA: American Cancer Society; 2008.
2. Sugimura H, Yang P. Long-term survivorship in lung cancer: a review. Chest. 2006;129:1088-1097.
3. Dagnelie P, Pijls-Johannesma M, Lambin P. Impact of fatigue on overall quality of life in lung and breast cancer patients selected for high-dose radiotherapy. Ann Oncol. 2007;18:940-944.
4. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR. Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer. 2001;30:233-240.
5. Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008;26:1355-1363.
6. Sprangers M, Schwartz CE. Integrating response shift into health-related quality of life research: a theoretical model. Soci Sci Med. 1999;48:1507-1515.
7. Nackley AG, Shabalina SA. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science. 2006;314:1930-1933.
8. McGuffin P, Cohen S. Homing in on depression genes. Am J Psychiatry. 2007;164:195-197.
9. Zubieta JK, Heitzeg MM. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299:1240-1243.
10. Diatchenko L, Slade GD. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet. 2005;14:135-143.
11. Levinson DF, Evgrafov OV. Genetics of recurrent early-onset major depression (GenRED): significant linkage on chromosome 15q25-q26 after fine mapping with single nucleotide polymorphism markers. Am J Psychiatry. 2007;164:259-264.
12. Holmans P, Weissman MM, Genetics of recurrent early-onset major depression (GenRED): final genome scan report. Am J Psychiatry. 2007;164:248-258.
13. Folkman S. Psychological effects of HIV infection. In: Goldberger L, Breznitz S, eds. Handbook of Stress: Theoretical and Clinical Aspects. 2nd ed. New York, NY: Free Press; 1993:658-681.
14. Kiecolt Glaser JK, Robles TF, Heffner KL, Loving TJ, Glaser R. Psycho-oncology and cancer: psychoneuroimmunology and cancer. Eur Soc Med Oncol. 2002;10:165-169.
15. Smith JC. Understanding Stress and Coping. New York, NY: Macmillan; 1993.
16. Marucha PT, Crespin TR, Shelby RA, Andersen BL. TNF-α levels in cancer patients relate to social variables. Brain Behav Immun. 2005;19:521-525.
17. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med. 2002;64:604-611.
18. Uchino BN, Cacioppo JT, Kiecolt-Glaser JK. The relationship between social support and physiological processes: a review with emphasis on underlying mechanisms and implications for health. Psychol Bull. 1996;119:488-531.
19. Kiecolt-Glaser J, Glaser R. Methodological issues in behavioral immunology research with humans. Brain Behav Immun. 1998;2:67-78.
20. Alexandrakis M. Serum proinflammatory cytokines and its relationship to clinical parameters in lung cancer patients with reactive thrombocytosis. Respir Med. 2002;96:553-558.
21. Costanzo ES, Lutgendorf SK, Sood AK, Anderson B, Sorosky J, Lubaroff DM. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer. 2005;104:305-313.
22. Savard J, Simard S, Ivers H, Morin CM. Randomized study on the efficacy of cognitive behavioral therapy for insomnia secondary to breast cancer, part II: immunologic effects. J Clin Oncol. 2005;23:6097-6106.
23. Thornton LM, Andersen BL, Crespin TR, Carson WE. Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments. Brain Behav Immun. 2006;21:185-194.
24. Marucha PT, Crespin TR, Shelby RA, Andersen BL. TNF-alpha levels in cancer patients relate to social variables. Brain Behav Immun. 2005;19:521-535.
25. Ah DV, Kang DH, Carpenter JS. Stress, optimism and social support: Impact on immune responses in breast cancer. Res Nurs Health. 2001;30:72-83.
26. Sephton SE, Koopman C, Schaal M, Thoresen C, Spiegel D. Spiritual expression and immune status in women with breast cancer. Breast J. 2001;7:345-353.
27. Schneiderman N, Antoni M, Saab PG, Ironson G. Health psychology: psychosocial and biobehavioral aspects of chronic disease management. Annu Rev Psychol. 2001;52:555-580.
28. Turner-Cobb JM, Sephton SE, Spiegel D. Psychosocial effects on immune function and disease progression in cancer: human studies. In: Adler R, Felten DL, Cohen DLN, eds. Psychoneuroimmunology. Vol 1. 3rd ed. San Diego, CA: Academic Press; 2001:565-582.
29. Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nature. 2008;8:887-899.
30. Hinds DA. Whole-genome patterns of common DNA variation in 3 human populations. Science. 2005;307:1072-1079.
31. Brull DJ, Montgomery HE, Sanders J, et al. Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol. 2001;21:1458-1463.
32. deMaat MP, Bladbjerg EM, Hjelmborg JB, et al. Genetic influence on inflammation variables in the elderly. Arterioscler Thromb Vasc Biol. 2004;24:2168-2173.
33. de Craen AJ, Posthuma D, Remarque EJ, et al. Heritability estimates of innate immunity: an extended twin study. Genes Immun. 2005;6:167-170.
34. Burzotta F, Iacoviello L, Di Castelnuovo A, et al. Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol. 2001;88:1125-1128.
35. Johnson VJ, Yucesoy B, Luster MI. Genotyping of single nucleotide polymorphisms in cytokine genes using real-time PCR allelic discrimination technology. Cytokine. 2004;27:135-141.
36. Shimura T, Haihara M, Takebe K. The study of tumor necrosis factor beta gene polymorphism in lung cancer patients. Cancer. 1994;73:1184-1188.
37. Hagihara M, Shimura T, Sato K, Genga K, Suzuki M, Tsuji K. HLA and tumor necrosis factor beta gene polymorphisms in Okinawa lung cancer patients: comparative study with mainland Japan lung cancer patients. Human Immun. 1995;43:95-100.
38. Lind H, Zienolddiny S, Ryberg D, Skaug V, Phillips DH, Haugen A. Interleukin-1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene. Lung Cancer. 2006;54:261-263.
39. Shih CM, Lee YL, Chiou HL, et al. The involvement of genetic polymorphisms of IL-10 promoter in non-small cell lung cancer. Lung Cancer. 2005;50:291-297.
40. Van Dyke AL, Cote ML, Wenzlaff AS, et al. Cytokine and cytokine receptor single-nucleotide polymorphisms predict risk for non-small cell lung cancer among women. Cancer Epidemiol Biomarkers Prev. 2009;18:1829-1840.
41. Shih CM, Lee YL, Chiou HL, et al. Association of TNF-alpha polymorphism with susceptibility to and severity of non-small cell lung cancer. Lung Cancer. 2006;52:15-20.
42. Reyes-Gibby CC, Spitz M, Wu X, et al. Cytokine genes and pain severity in lung cancer: exploring the influence of TNF-α-308 G/A IL-6-174G/C and IL8-251T/A. Cancer Epidemiol Biomarkers Prev. 2007;16:2745-2751.
43. Collado-Hidalgo A, Bower JE, Ganz PA, Irwin MR, Cole S. Cytokine gene polymorphisms and fatigue in breast cancer survivors: early findings. Brain Behav Immun. 2008;22:1197-2000.
44. Yang P, Allen MS, Aubry MC. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005;128:452-462.
45. Svobodnik A, Yang P, Novotny PJ. Quality of life in 650 lung cancer survivors 6 months to 4 years after diagnosis. Mayo Clin Proc. 2004;79:1024-1030.
46. Ware JE, Kosinski M. SF-36 physical and mental health summary scales: a manual for users. Lincoln, RI: Quality Metric; 2001.
47. Colgrove LA, Kim Y, Thompson N. The effect of spirituality on the quality of life of spousal caregivers of cancer survivors. Ann Behav Med. 2007;33:90-98.
48. Land S, Wickerham DL, Costantino JP, et al. The study of tamoxifen and raloxifene (STAR): first report of patient-reported outcomes (PROs) from the NSABP P-2 breast cancer prevention study. JAMA. 2006;295:2742-2751.
49. Mosconi P, Cifani S, Crispino S, Fossati R, Apolone G. The performance of SF-36 health survey in patients with laryngeal cancer. Head and Neck Cancer Italian Working Group. Head Neck. 2000;22:175-182.
50. Hollen PJ, Gralla RJ, Kris MG, Cox C. Quality of life during clinical trials: Conceptual model for the Lung Cancer Symptom Scale (LCSS). Support Care Cancer. 1994;2:213-222.
51. Hollen PJ, Gralla RJ, Kris MG, Cox C, Belani CP, Grunberg SM. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies: psychometric assessment of the Lung Cancer Symptom Scale. Cancer. 1994;73:2087-2098.
52. Hollen PJ, Gralla RJ, Kris MG, Eberly SW, Cox C. Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS). Support Care Cancer. 1999;7:140-148.
53. de Marinis F, Pereira JR, Fossella F, et al. Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of premetrexed versus docetaxel in advanced non-small cell lung cancer. J Thorac Oncol. 2008;3:30-36.
54. Hollen PJ, Gralla RJ, Liepa AM, et al. Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso. Support Care Cancer. 2006;14:11-21.
55. Hollen PJ, Gralla RJ, Kris MG, McCoy S, Donaldson GW, Moinpour CM. A comparison of visual analogue and numerical rating scale formats for the Lung Cancer Symptom Scale (LCSS): does format affect patient ratings of symptoms and quality of life? Qual Life Res. 2005;14:837-847.
56. Hassan MI, Aschner A, Manning CH, Xu J, Aschner JL. Racial differences in selected cytokine allelic and genotypic frequencies among healthy, pregnant women in North Carolina. Cytokine. 2003;21:10-16.
57. Belsey DA, Kuh E, Welsch RE. Regression Diagnostics: Identifying Influential Data and Sources of Colinearity. New York, NY: John Wiley & Sons; 1980.
58. Hefler LA, Grimm C, Lantzsch T. Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in Caucasian women. Clin Cancer Res. 2005;11:5718-5721.
59. Smith KC, Bateman AC, Fussell HM, Howell WM. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet. 2004;31:167-173.
60. Hopwood P, Thatcher N. Preliminary experience with quality of life evaluation in patients with lung cancer. Oncology. 1990;4:158-162.
61. Maier SF, Watkins LR. Immune-to-central nervous system communication and its role in modulating pain and cognition: implications for cancer and cancer treatment. Brain Behav Immun. 2003;17(suppl 1):S125-S131.
62. Schafers M, Sommer C. Anticytokine therapy in neuropathic pain management. Expert Rev Neurother. 2007;7:1613-1627.
63. Bower JE. Prevalence and causes of fatigue after cancer treatment: the next generation of research. J Clin Oncol. 2005;23:8280-8282.
64. Jacobsen PB, Donovan KA, Small BJ, Jim HS, Munster P, Andrykowski MA. Fatigue following treatment for early stage breast cancer: a controlled comparison. Cancer. 2007;110:1851-1859. (Pubitemid 47557311)
65. Broeckel JA, Jacobsen PB, Horton J. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol. 1998;16:1689-1696.
66. Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun. 2007;21:413-427.
67. Malik UR, Makower DF, Wadler S. Interferon-mediated fatigue. Cancer. 2001;92(6 suppl):1664-1668.
68. Hieber U, Heim ME. Tumor necrosis factor for the treatment of malignancies. Oncology. 1994;51:142-153.
69. Sosman JA, Aronson FR, Sznol M, et al. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity. Clin Cancer Res. 1997;3:39-46.
70. Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. Chest. 1986;89:234-236.
71. Sarna L, Riedinger MS. Assessment of quality of life and symptom improvement in lung cancer clinical trials. Semin Oncol. 2004;31(3 Suppl 9):1-10.
72. Garrod R, Ansley P, Canavan J, Jewell A. Exercise and the inflammatory response in chronic obstructive pulmonary disease (COPD): does training confer anti-inflammatory properties in COPD? Med Hypotheses. 2007;68:291-298.
73. Seifart C, Plagens A, Dempfle A, Clostermann U, Vogelmeier C. TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers. 2005;21:157-165.
74. Laviano A, Meguid MM, Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol. 2003;4:686-694.
75. Jatoi A, Nguyen PL, Foster N, et al. Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinoma. J Support Oncol. 2007;5:41-46.
76. Zhang D, Zheng H, Zhou Y, Tang X, Yu B, Li J. Association of IL-1beta gene polymorphism with cachexia from locally advanced gastric cancer. BMC Cancer. 2007;7:45.
77. Yoder LH. An overview of lung cancer symptoms, pathophysiology, and treatment. Medsurg Nurs. 2006;15:231-234.
78. Ruckdeschel JC, Piantadosi S. Quality of life in lung cancer surgical adjuvant trials. Chest. 1994;106(6 suppl):324S-328S.
79. Ganz PA, Lee JJ, Siau J. Quality of life assessment. An independent prognostic variable for survival in lung cancer. Cancer. 1991;67:3131-3135.
80. Bernhard J, Ganz PA. Psychosocial issues in lung cancer patients (pt 1). Chest. 1991;99:216-223.
81. Bernhard J, Ganz PA. Psychosocial issues in lung cancer patients (pt 2). Chest. 1991;99:480-485.